Cite
Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19
MLA
Benedetta Mazzanti, et al. “Cord Blood-Derived Cytokine-Induced Killer Cells Combined with Blinatumomab as a Therapeutic Strategy for CD19.” Cytotherapy, vol. 20, no. 8, Dec. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8fd4dc964f522ebc407eb66c7466ef49&authtype=sso&custid=ns315887.
APA
Benedetta Mazzanti, Riccardo Saccardi, Sabrina Cribioli, Josée Golay, Martino Introna, Elisa Gotti, Simona Martinelli, Rachele Alzani, Clara Albanese, Alessandro Rambaldi, & Bruna Pasini. (2017). Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19. Cytotherapy, 20(8).
Chicago
Benedetta Mazzanti, Riccardo Saccardi, Sabrina Cribioli, Josée Golay, Martino Introna, Elisa Gotti, Simona Martinelli, et al. 2017. “Cord Blood-Derived Cytokine-Induced Killer Cells Combined with Blinatumomab as a Therapeutic Strategy for CD19.” Cytotherapy 20 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8fd4dc964f522ebc407eb66c7466ef49&authtype=sso&custid=ns315887.